<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931161</url>
  </required_header>
  <id_info>
    <org_study_id>EVOCAR-1</org_study_id>
    <nct_id>NCT03931161</nct_id>
  </id_info>
  <brief_title>Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)</brief_title>
  <acronym>EVOCAR-1</acronym>
  <official_title>Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV, randomised, placebo-controlled, double-blind, parallel group study to&#xD;
      determine the effect of Evolocumab treatment on carotid plaque morphology and composition in&#xD;
      asymptomatic patients with &gt;50% carotid artery stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study patients will be randomised in a 1:1 ratio to receive Evolocumab 140 mg every&#xD;
      two weeks or matching placebo, to be administered for 12 months. After 12 months of&#xD;
      treatment, patients will remain in follow-up for a further 12 months.&#xD;
&#xD;
      High resolution magnetic resonance imaging (MRI) will be used to serially monitor the impact&#xD;
      of Evolocumab on carotid plaque morphology and composition in patients with significant&#xD;
      carotid stenosis who do not meet clinical criteria for carotid endarterectomy. This approach&#xD;
      will reveal if clinically beneficial plaque regression occurs, without requiring the large&#xD;
      patient cohorts or long follow-up needed for cardiovascular outcome trials.&#xD;
&#xD;
      Results from this study will establish whether treatment with Evolocumab is likely to be&#xD;
      beneficial to patients with asymptomatic carotid stenosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">September 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lipid-rich necrotic core</measure>
    <time_frame>12 months</time_frame>
    <description>Change in lipid-rich necrotic core (LRNC) size at 12 months, compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of LRNC core</measure>
    <time_frame>12 months</time_frame>
    <description>Change in percentage lipid-rich necrotic core (LRNC) at 12 months, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRNC regression</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants achieving LRNC regression at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRNC volume</measure>
    <time_frame>24 months</time_frame>
    <description>Change in carotid plaque LRNC volume at other time-points, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRNC percentage</measure>
    <time_frame>24 months</time_frame>
    <description>Change in carotid plaque LRNC percentage at other time-points, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of other carotid plaque burden - Volume wall thickness</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change, compared to baseline, of volume wall thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of other carotid plaque burden - Volume wall area</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change, compared to baseline, volume wall area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of other carotid plaque burden - Calcification</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change, compared to baseline, of plaque composition (calcification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of other carotid plaque burden - Fibrous tissue volume</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change, compared to baseline, of plaque composition (fibrous tissue volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of other carotid plaque burden - New intra-plaque haemorrhage</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change, compared to baseline, of plaque composition (new intra-plaque haemorrhage)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 1: Change in biochemical parameters - total cholesterol</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change compared to baseline in total cholesterol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 1: Change in biochemical parameters - LDL-C</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change compared to baseline in LDL-C.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 1: Change in biochemical parameters - HDL-C</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change compared to baseline in high density lipoprotein-associated cholesterol (HDL-C).</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 1: Change in biochemical parameters - triglycerides</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change compared to baseline in triglycerides.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 1: Change in biochemical parameters - lipoprotein (a)</measure>
    <time_frame>24 months</time_frame>
    <description>Absolute and percentage change compared to baseline in lipoprotein(a).</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 2: Number of patients with Cardio &amp; cerebrovascular events - Ischaemic and non-ischaemic stroke</measure>
    <time_frame>24 months</time_frame>
    <description>Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Ischaemic and non-ischaemic stroke</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 2: Number of patients with Cardio &amp; cerebrovascular events - TIA</measure>
    <time_frame>24 months</time_frame>
    <description>Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Transient ischaemic attack</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 2: Number of patients with Cardio &amp; cerebrovascular events - Progression to carotid endarterectomy</measure>
    <time_frame>24 months</time_frame>
    <description>Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Progression to carotid endarterectomy</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 2: Number of patients with Cardio &amp; cerebrovascular events - MI</measure>
    <time_frame>24 months</time_frame>
    <description>Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 2: Number of patients with Cardio &amp; cerebrovascular events - Unstable angina</measure>
    <time_frame>24 months</time_frame>
    <description>Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Unstable angina</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 2: Number of patients with Cardio &amp; cerebrovascular events - Hospitalisation for heart failure</measure>
    <time_frame>24 months</time_frame>
    <description>Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: Hospitalisation for heart failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes 2: Number of patients with Cardio &amp; cerebrovascular events -PAD-related end points: peripheral revascularization,</measure>
    <time_frame>24 months</time_frame>
    <description>Cardio- and cerebrovascular events [be adjudicated by the Investigators], including: PAD-related end points: peripheral revascularization,</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evolocumab Auto-Injector [Repatha]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab Auto-Injector [Repatha]</intervention_name>
    <description>Auto-Injector, 140 mg every two weeks.</description>
    <arm_group_label>Evolocumab</arm_group_label>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Auto-Injector</intervention_name>
    <description>Matching Placebo for the active comparator (Evolocumab)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Sufficient English language ability to adequately understand the study&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Significant carotid artery plaque with 50-70% stenosis on ultrasound or MRI performed&#xD;
             prior to screening&#xD;
&#xD;
          -  Significant asymptomatic carotid artery plaque with &gt;70% stenosis on ultrasound or MRI&#xD;
             performed prior to screening, but carotid endarterectomy or carotid artery stenting&#xD;
             has been deemed unsuitable by multidisciplinary team during routine clinical care&#xD;
&#xD;
          -  Lipid-rich necrotic core (LRNC) on baseline MRI scan&#xD;
&#xD;
          -  Adequate image quality for MRI analysis.&#xD;
&#xD;
          -  LDL-C ≥2.6 mmol/L (100 mg/dL)&#xD;
&#xD;
          -  On stable dose of maximally-tolerated lipid-lowering therapy in accordance with UK&#xD;
             national clinical guidelines (NICE CG18120) for ≥2 months prior to screening.&#xD;
             Acceptable non-statin lipid-lowering medications include ezetimibe or a fibrate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition which, in the opinion of the investigators, would present an&#xD;
             unacceptable risk to the participant if they were to take part in the trial, or&#xD;
             prevent them from following the trial protocol&#xD;
&#xD;
          -  Current or previous treatment with a PCSK9 inhibitor&#xD;
&#xD;
          -  Eligible for PCSK9 inhibitor treatment under current NICE guidelines&#xD;
&#xD;
          -  Contra-indication to or inability to use Evolocumab treatment, including:&#xD;
&#xD;
               -  Sensitivity to Evolocumab or any associated excipients&#xD;
&#xD;
               -  Unable to tolerate or perform self-administration of Evolocumab by auto-injector&#xD;
&#xD;
               -  Lack of suitable refrigerated storage&#xD;
&#xD;
          -  Contra-indication to or inability to tolerate MRI&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≤45 mL/min/1.73 m2 prior to MRI scan&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Women of childbearing potential who are unwilling or unable to use a highly effective&#xD;
             method of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaimini Cegla, BSc MSc MBBS MRCP FRCPath PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaimini Cegla, BSc MSc MBBS MRCP FRCPath PhD</last_name>
    <phone>+44 20 3313 3405</phone>
    <email>j.cegla@imperial.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaimini Cegla</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carotid plaque morphology</keyword>
  <keyword>carotid plaque composition</keyword>
  <keyword>evolocumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

